Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.68 |
| ▸ | CA2 | P00918 | 3/20 | 0.68 |
| ▸ | CA1 | P00915 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | CA12 | O43570 | 1/20 | 0.68 |
| ▸ | CA4 | P22748 | 1/20 | 0.68 |
| ▸ | CA6 | P23280 | 1/20 | 0.68 |
| ▸ | CA5A | P35218 | 1/20 | 0.68 |
| ▸ | CA7 | P43166 | 1/20 | 0.68 |
| ▸ | CA9 | Q16790 | 1/20 | 0.68 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.68 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29132639 | 0.85 | LMNA (0.79) | LMNACA2CA1HTTCA12 | |
| SCHEMBL30561865 | 0.85 | LMNA (0.79) | LMNACA2CA1HTTCA12 | |
| Trichlormethiazide SCHEMBL29356280 | 0.81 | LMNA (1.00) | LMNACA2CA1HTTCA12 | |
| Trichlormethiazide SCHEMBL25492 | 0.81 | LMNA (1.00) | LMNACA2CA1HTTCA12 | |
| Trichlormethiazide SCHEMBL25493 | 0.81 | LMNA (1.00) | LMNACA2CA1HTTCA12 | |
| Mebutizide SCHEMBL323002 | 0.79 | LMNA (0.69) | LMNACA2CA1HTTCA12 | |
| Mebutizide SCHEMBL29357329 | 0.79 | LMNA (0.69) | LMNACA2CA1HTTCA12 | |
| SCHEMBL5625913 | 0.78 | ALDH1A1 (0.67) | LMNACA2CA1HTTCA12 | |
| SCHEMBL30561858 | 0.78 | ALDH1A1 (0.67) | LMNACA2CA1HTTCA12 | |
| SCHEMBL29132609 | 0.76 | TDP1 (0.70) | LMNACA2CA1HTTCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 349 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025093735-A2 | AGENTS FOR USE IN THE TREATMENT OF TAUOPATHIES | DRUG TARGET IP B.V. (NL) | 2025-05-08 | — | — | WO | claimed |
| US-20240002935-A1 | GENETIC METHOD FOR DIAGNOSIS AND TREATMENT OF PRE AND POST CORONAVIRUS INFECTIONS | GENETICURE INC. | 2024-01-04 | — | — | US | claimed |
| EP-4132653-A1 | GENETIC METHOD FOR DIAGNOSIS AND TREATMENT OF PRE AND POST CORONAVIRUS INFECTIONS | Geneticure Inc. (US) | 2023-02-15 | — | — | EP | claimed |
| US-10590485-B2 | Therapeutic regimen for hypertension | GENETICURE LLC (US) | 2020-03-17 | — | — | US | claimed |
| EP-3149487-B1 | IMPROVED THERAPEUTIC REGIMEN FOR HYPERTENSION | GENETICURE LLC (US) | 2020-02-12 | — | — | EP | claimed |
| US-20180195128-A1 | Therapeutic Regimen for Hypertension | GENETICURE INC. | 2018-07-12 | — | — | US | claimed |
| CN-107596375-A | A kind of drug compound preparation for treating hypertensive obesity patient and preparation method thereof | 郭裴哲 | 2018-01-19 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100323012-A1 | Pharmaceutical Compositions Comprising NEP-Inhibitors, Inhibitors of the Endogenous Endothelin Producing System and Diuretics | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-12-23 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20030060489-A1 | Novel method of treatment | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-03-27 | — | — | US | claimed |
| EP-1261373-A2 | COMPOSITION FOR THE TREATMENT DIABETES MELLITUS CONTAINING AN INSULINE SENSITIZER AND AGENT USED IN THE TREATMENT OF CARDIAC CONDITIONS | SmithKline Beecham plc (GB) | 2002-12-04 | — | — | EP | claimed |
| WO-2001047509-A2 | COMPOSITION FOR THE TREATMENT DIABETES MELLITUS CONTAINING AN INSULINE SENSITIZER AND AGENT USED IN THE TREATMENT OF CARDIAC CONDITIONS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-07-05 | — | — | WO | claimed |
| CN-1279615-A | Use of a combination of a invertase inhibitor and a diuretic for the treatment of microcirculation disorders | ADIR (FR) | 2001-01-10 | — | — | CN | claimed |
| EP-1032414-A1 | COMBINATION OF HYPERTENSIN CONVERTING ENZYME INHIBITOR WITH A DIURETIC FOR TREATING MICROCIRCULATION DISORDERS | ADIR ET COMPAGNIE (FR) | 2000-09-06 | — | — | EP | claimed |
| WO-1999025374-A1 | COMBINATION OF HYPERTENSIN CONVERTING ENZYME INHIBITOR WITH A DIURETIC FOR TREATING MICROCIRCULATION DISORDERS | ADIR ET COMPAGNIE (FR) | 1999-05-27 | — | — | WO | claimed |
| EP-0643580-A4 | COMBINATIONS OF ACE INHIBITORS AND DIURETICS. | — | 1995-04-19 | — | — | EP | claimed |
| EP-0643580-A1 | COMBINATIONS OF ACE INHIBITORS AND DIURETICS | MERCK & CO. INC. (US) | 1995-03-22 | — | — | EP | claimed |
| WO-1994009778-A1 | COMBINATIONS OF ANGIOTENSIN-II RECEPTOR ANTAGONISTS AND DIURETICS | MERCK & CO., INC. (US) | 1994-05-11 | — | — | WO | claimed |
| WO-1993017685-A1 | COMBINATIONS OF ACE INHIBITORS AND DIURETICS | MERCK & CO., INC. (US) | 1993-09-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323012-A1 | Pharmaceutical Compositions Comprising NEP-Inhibitors, Inhibitors of the Endogenous Endothelin Producing System and Diuretics | ECE1, EDNRA, MME | LMNA 410/4885CA2 555/4885CA1 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.